Menu

More Retractions for Tokyo Scientist?

A university panel has detected irregularities in 43 papers by Shigeaki Kato.

Jul 26, 2013
Kate Yandell

FLICKR, ROBERT CUDMOREA University of Tokyo panel is recommending that former university scientist Shigeaki Kato withdraw 43 scientific papers, according to the Asahi Shimbun, a Japanese newspaper.

The recommendations are the result of an investigation that was triggered last year (January 2012) when an anonymous tipster made a Youtube video chronicling allegedly fraudulent manipulations made to figures in Kato’s papers. Kato resigned from his position at the university in March 2012. According to Retraction Watch, five papers by Kato have already been retracted.

The University of Tokyo told ScienceInsider that the panel’s report has not yet been released and did not confirm the assertions made by Asahi Shumbun.

According to the Japanese newspaper, the committee reviewed 165 papers and found questionable material in 43 of them. The problems included duplicated and reversed images, as well as forgery.

Kato told Asahi Shumbun that he planned to withdraw the papers. “There certainly were irregularities,” he said. “I used to place trust on the members of my lab. I have a major responsibility as a supervisor.”

The Asahi Shumbun noted that some of Kato’s collaborators who got their degrees based on the questionable papers could have them revoked. More than 20 scientists were coauthors on the 43 papers.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.